Halozyme Therapeutics Inc. told investors that it expected to sign one new deal before the end of 2017 for the use of its Enhanze drug delivery technology and the company followed through on that promise with its largest transaction to date: a deal with Bristol-Myers Squibb Co.worth up to $1.87bn.
San Diego-based Halozyme President and CEO Helen Torley said in an interview that the deal, along with an expansion of an existing partnership with Roche, marks a transition for Enhanze, which can be used to formulate intravenously administered drugs as subcutaneous injections
